New technique may help quicken production of blood cancer drug

Researchers at Madurai Kamaraj University have developed a technique that promises to quicken the process of production of L-asparaginase, an enzyme used in treatment of acute lymphoblastic leukaemia.
Human cells need steady supply of an amino acid, Asparagine, to build proteins and use an enzyme called asparagine synthetase to make it. Cancerous cells, however, rely on blood for their requirement of asparagine. 
L-Asparaginase therapy takes advantage of this. L-Asparaginase enzyme performs the opposite reaction to asparagine synthetase. It catalyses conversion of L-asparagine to aspartic acid and ammonia. If a large dose of this enzyme is introduced into the blood, it will circulate and continually break down all asparagine that it finds, ultimately starving the cells that depend on blood for asparagine supply.
L-Asparaginase is an effective therapy for those cases where blood cells become cancerous, such as in acute lymphoblastic leukemia. L-Asparaginase cuts off the supply of asparagine in blood and cancer cells die as they are unable to build their proteins. It is produced from various microbes including a marine bacterium called Bacillus tequilensis PV9W. 
Researchers cloned the gene coding for L-asparaginase from Bacillus tequilensis PV9W and expressed it in Escherichia coli BL21 bacterium. In just 12 hours they could produce as much quantity of recombinant enzyme as the native Bacillus tequilensis PV9W could do in 48 hours. “We have been able to cut down the production time by 75 per cent at the laboratory scale. It should be possible to extrapolate the process at commercial scale,” explained P Varalakshmi, leader of the research team, while speaking to India Science Wire. 
The team has also developed another technique that promises to improve shelf life of the L-asparaginase enzyme and enhance its activity. Researchers encapsulated native L-asparaginase of Bacillus tequilensis PV9W using solid lipid particles and hot lipid emulsion. “Tests showed that the encapsulated enzyme was stable for 25 days even when stored at 25 degrees as compared to the native enzyme which needed refrigerated conditions,” researchers said.
The enzyme has been tested on cervical cancer cell line. “The cytotoxicity ability of the particle was found to be highly enhanced compared to the native L-asparaginase from Bacillus tequilensis PV9W,” they said.
In addition, the team has found that lipid encapsulated enzyme could be used to detect L-asparagine in cell extracts using electrochemistry method, Differential Pulse Voltammetry (DPV). This work was done in collaboration with researchers at Central Electro Chemical Research Institute (CECRI) at Karaikudi. Researchers coated a glassy carbon electrode with the lipid encapsulated enzyme and found that there was a difference in the generated current when the electrode was in contact with L- asparagine. This means lipid encapsulated enzyme  could possibly be used as a biosensor to monitor the cancer progression and treatment by L-asparaginase.
Besides Varalakshmi, the research team included senior scientist V Ganesh of CECRI, VS Vasantha of School of Chemistry at MKU, B Ashok Kumar, School of Genetic Engineering, MKU and research scholars G Shakambari, and Sameer Kumar Rai. The findings have been published in journal Scientific Reports. (India Science Wire)
Source:https://www.downtoearth.org.in/news/health/new-technique-may-help-quicken-production-of-blood-cancer-drug-63201

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more